Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 13 04:00PM ET
3.05
Dollar change
-0.03
Percentage change
-0.97
%
IndexRUT P/E- EPS (ttm)-11.00 Insider Own4.63% Shs Outstand23.46M Perf Week-14.80%
Market Cap71.55M Forward P/E- EPS next Y-8.91 Insider Trans0.00% Shs Float22.37M Perf Month0.66%
Income-227.86M PEG- EPS next Q-2.64 Inst Own33.66% Short Float12.31% Perf Quarter-49.84%
Sales160.43M P/S0.45 EPS this Y11.83% Inst Trans-3.98% Short Ratio5.65 Perf Half Y-80.27%
Book/sh-13.48 P/B- EPS next Y26.78% ROA-79.32% Short Interest2.75M Perf Year-81.49%
Cash/sh1.91 P/C1.60 EPS next 5Y- ROE- 52W Range2.50 - 19.69 Perf YTD-81.58%
Dividend Est.- P/FCF- EPS past 5Y13.79% ROI- 52W High-84.51% Beta1.25
Dividend TTM- Quick Ratio0.19 Sales past 5Y98.93% Gross Margin90.08% 52W Low22.00% ATR (14)0.33
Dividend Ex-Date- Current Ratio0.19 EPS Y/Y TTM32.67% Oper. Margin-62.83% RSI (14)40.51 Volatility7.62% 11.13%
Employees389 Debt/Eq- Sales Y/Y TTM59.00% Profit Margin-142.03% Recom2.60 Target Price7.75
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q6.36% Payout- Rel Volume0.86 Prev Close3.08
Sales Surprise-24.99% EPS Surprise-33.12% Sales Q/Q3.28% EarningsNov 12 BMO Avg Volume487.34K Price3.05
SMA20-5.08% SMA50-20.51% SMA200-63.92% Trades Volume417,110 Change-0.97%
Date Action Analyst Rating Change Price Target Change
Jul-19-24Downgrade Robert W. Baird Outperform → Neutral $35 → $8
Jul-18-24Downgrade William Blair Outperform → Mkt Perform
Jul-18-24Downgrade H.C. Wainwright Buy → Neutral $9
Jun-06-23Initiated Robert W. Baird Outperform $8
Jun-06-23Initiated Robert W. Baird Outperform $60 → $80
Feb-28-23Resumed H.C. Wainwright Buy $8
Sep-28-22Initiated SMBC Nikko Outperform $5
Dec-16-21Initiated H.C. Wainwright Buy $12
Nov-19-19Resumed B. Riley FBR Buy $6
Apr-22-19Initiated B. Riley FBR Buy
Dec-06-24 06:07AM
Dec-05-24 07:30AM
Nov-27-24 10:20AM
08:15AM
Nov-19-24 09:35AM
09:35AM Loading…
Nov-18-24 09:35AM
Nov-15-24 09:35AM
Nov-13-24 02:18AM
02:08AM
Nov-12-24 12:15PM
08:20AM
07:19AM
07:00AM
Nov-11-24 07:24AM
Nov-07-24 10:00AM
07:00AM Loading…
07:00AM
Nov-05-24 07:30AM
Nov-01-24 05:45AM
Oct-29-24 05:45AM
Sep-19-24 01:31PM
Sep-17-24 05:45AM
Sep-16-24 12:51PM
Sep-13-24 10:00AM
Sep-09-24 07:30AM
Sep-03-24 07:30AM
Aug-08-24 04:15PM
08:10AM
07:08AM
07:00AM
07:00AM
10:58AM Loading…
Aug-07-24 10:58AM
Aug-05-24 02:31PM
07:23AM
Aug-01-24 10:01AM
Jul-26-24 07:00AM
Jul-19-24 10:39AM
07:47AM
Jul-18-24 07:00AM
Jun-28-24 11:10AM
Jun-27-24 07:30AM
Jun-17-24 07:00AM
Jun-13-24 05:15AM
Jun-04-24 07:30AM
May-30-24 03:30PM
May-27-24 12:32PM
May-24-24 05:00PM
May-23-24 05:10PM
07:30AM
May-22-24 07:30AM
May-16-24 07:30AM
May-08-24 01:22PM
11:11AM
03:09AM
May-07-24 05:45PM
01:52PM
12:24PM
09:00AM
08:56AM
07:59AM
07:40AM
07:30AM
May-01-24 07:30AM
Apr-28-24 08:30AM
Apr-24-24 10:00AM
Apr-23-24 07:30AM
Apr-22-24 04:17AM
Apr-12-24 07:30AM
Apr-08-24 03:34AM
Apr-05-24 04:30PM
Apr-03-24 04:19AM
Mar-24-24 04:05PM
Mar-22-24 01:25PM
Mar-15-24 02:11PM
Mar-14-24 01:30PM
08:51AM
07:39AM
07:30AM
Mar-06-24 07:30AM
Mar-05-24 04:30PM
Feb-29-24 07:30AM
Feb-26-24 07:30AM
Feb-15-24 06:38PM
07:02AM
Feb-01-24 07:09PM
Jan-31-24 07:30AM
Jan-26-24 03:57PM
Jan-22-24 07:30AM
Jan-05-24 04:30PM
Jan-04-24 07:30AM
Dec-24-23 09:45AM
Dec-20-23 07:30AM
Dec-11-23 07:30AM
Nov-07-23 06:55AM
06:41AM
06:30AM
Oct-26-23 09:05AM
Oct-22-23 12:00PM
Oct-21-23 04:15AM
Oct-10-23 07:30AM
Oct-05-23 07:30AM
Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ARMEN GARO HSee RemarksFeb 15 '24Buy0.65500,000324,050625,969Feb 15 06:59 PM